Functional outcomes in schizophrenia

Journal of Clinical Psychiatry

Volumn 69, Issue SUPPL. 3, 2008, Pages 20-24

  McEvoy, Joseph P ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JUH Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

COGNITION; COGNITIVE DEFECT; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EMPLOYMENT; FAMILIAL THERAPY; HUMAN; JOB SATISFACTION; LEARNING; MEMORY DISORDER; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOSOCIAL CARE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL ADAPTATION; SUBSTANCE ABUSE; ADDICTION; CASE MANAGEMENT; REMISSION; SOCIAL SUPPORT; TREATMENT OUTCOME;

CASE MANAGEMENT; COGNITION DISORDERS; EMPLOYMENT; HUMANS; REMISSION INDUCTION; SCHIZOPHRENIA; SOCIAL SUPPORT; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 46649092795     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449
2. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-131
3. Harvey PD, Keefe RSE. Cognitive impairment in schizophrenia and implications for atypical neuroleptic treatment. CNS Spect 1997;2:1-11
4. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-445
5. Reichenberg A, Weiser M, Rapp MA, et al. Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res 2006;85:49-57
6. Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 2004;172:324-332
7. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301-307
8. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31:2033-2046
9. Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005;162:495-506
10. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26:119-136
11. Jeste SD, Patterson TL, Palmer BW, et al. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res 2003;63:49-58
12. Chen EY, Hui CL, Dunn EL, et al. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr Res 2005;77:99-104
13. Velligan DI, Kern RS, Gold JM. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull 2006;32:474-485
14. Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997;54:313-321
15. Kavanagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002;62:743-755
16. Swartz MS, Wagner HR, Swanson JW, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv 2006;57:1110-1116
17. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-861
18. Swartz MS, Swanson JW, Hiday VA, et al. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry 1998;155:226-231
19. Swofford CD, Kasckow JW, Scheller-Gilkey G, et al. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996;20:145-151
20. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26:441-449
21. Pitschel-Walz G, Leucht S, Bäuml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia: a meta-analysis. Schizophr Bull 2001;27:73-92
22. Pharoah FM, Rathbone J, Mari JJ, et al. Family intervention for schizophrenia. Cochrane Database Syst Rev 2003;(4):CD000088
23. Linszen D, Dingemans P, Van der Does JW, et al. Treatment, expressed emotion and relapse in recent onset schizophrenic disorders. Psychol Med 1996;26:333-342
24. Nugter A, Dingemans P, Van der Does JW, et al. Family treatment, expressed emotion and relapse in recent onset schizophrenia. Psychiatry Res 1997;72:23-31
25. Hogarty GE, Kornblith SJ, Greenwald D, et al. Three-year trials of personal therapy among patients living with or independent of family, 1: description of study and effects on relapse rates. Am J Psychiatry 1997;154:1504-1513
26. Hogarty GE, Greenwald D, Ulrich RF, et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, 2: effects on adjustment of patients. Am J Psychiatry 1997;154:1514-1524
27. McFarlane WR, Dushay RA, Stastny P, et al. A comparison of two levels of family-aided assertive community treatment. Psychiatr Serv 1996;47:744-750
28. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30:193-217
29. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev 2000;(2):CD001089
30. Bustillo J, Lauriello J, Horan W, et al. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry 2001;158:163-175
31. Rosenheck RA, Neale MS. Cost-effectiveness of intensive psychiatric community care for high users of inpatient services. Arch Gen Psychiatry 1998;55:459-466
32. Salokangas RKR, Honkonen T, Stengard E, et al. Subjective life satisfaction and living situations of persons in Finland with long-term schizophrenia. Psychiatr Serv 2006;57:373-381
33. Marder SR, Wirshing WC, Mintz J, et al. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 1996;153:1585-1592
34. Spaulding WD, Reed D, Sullivan M, et al. The effects of cognitive treatment in psychiatric rehabilitation. Schizophr Bull 1999;25:291-307
35. Vauth R, Rusch M, Wirtz M, et al. Does social cognition influence the relation between neurocognitive deficits and vocational functioning in schizophrenia? Psychiatry Res 2004;128:155-165
36. Spaulding WD, Fleming SK, Reed D, et al. Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation. Schizophr Bull 1999;25:275-289
37. Bond GR, Becker DR, Drake RE, et al. Implementing supported employment as an evidence-based practice. Psychiatr Serv 2001;52:313-322
38. Mueser KT, Aalto S, Becker DR, et al. The effectiveness of skills training for improving outcomes in supported employment. Psychiatr Serv 2005;56:1254-1260
39. Lehman AF, Goldberg R, Dixon LB, et al. Improving employment outcomes for persons with severe mental illnesses. Arch Gen Psychiatry 2002;59:165-172
40. Hamilton SH, Edgell ET, Revicki DA, et al. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000;15:245-255
41. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262
42. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028
43. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187:312-320
44. Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs olanzapine. J Neuropsychiatry Clin Neurosci 2006;18:54-63
45. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725